Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study
Gynecologic and Obstetric Investigation · 2023
DOI: 10.1159/000530360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gynecologic and Obstetric Investigation, 2023. Verfasst von Valerie Strezsak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Global Clinical Development, Research and Development, EMD Serono Research and Development Institute, Inc., an affiliate of Merck KGaA, Billerica, Ma…. Hauptthemen laut MEDLINE: Semen, Infertility. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
The aim of the study was to evaluate dosing of recombinant human luteinizing hormone (r-hLH) or human menopausal gonadotrophin (hMG)-derived medications with LH activity in ovarian stimulation (OS) cycles for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).
Design
A non-interventional study was performed to analyse data from the German RecDate database (January 2007–December 2011). Participants/Materials, Setting, Methods: Starting/total r-hLH/hMG dose, OS duration/cycle number, r-hLH/hMG initiation day (first day of administration), and population/cycle characteristics were assessed in women (≥18 years) undergoing OS for IVF/ICSI using r-hLH or hMG-derived medications (excluding corifollitropin alfa, clomiphene citrate, letrozole, mini/micro-dose human chorionic gonadotrophin, and urofollitropin alone). Data were summarized descriptively.
Results
67,858 identified cycles utilized medications containing r-hLH (10,749), hMG (56,432), or both (677). Mean (standard deviation) OS duration with r-hLH and hMG was 10.1 (4.43) and 9.8 (6.16) days, respectively. Median (25th–75th percentile) r-hLH starting dose (75.0 [75.0–150.0] IU) was consistent across patients regardless of age, infertility diagnosis, or gonadotrophin-releasing hormone (GnRH) protocol. Median (25th–75th percentile) hMG-derived LH activity starting dose was 225.0 (150.0–300.0) IU, regardless of GnRH protocol, but was lower in women aged <35 years and those with ovulation disorders/polycystic ovary syndrome. Median (25th–75th percentile) total dose for r-hLH (750.0 [337.5–1,125.0] IU) and hMG-derived LH activity (1,575.0 [750.0–2,625.0] IU) varied according to patients’ age, infertility diagnosis, cycle number, and r-hLH/hMG initiation day. GnRH antagonist use resulted in a numerically higher median total hMG-derived LH activity dose than GnRH agonist use.
Limitations
The data used in this study were taken from electronic medical records relating to a specific timeframe (2007–2011) and therefore may not accurately reflect current clinical practice; however, it is likely that the differences between the two compounds would be maintained. Additionally, secondary data sources may suffer from uniformity and quality issues.
Conclusions
The standard of care for OS cycles is described with respect to IVF/ICSI treatment including an LH component in Germany during the specified timeframe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Clinical Development, Research and Development, EMD Serono Research and Development Institute, Inc., an affiliate of Merck KGaA, Billerica, Massachusetts, USA.
- Global Epidemiology, Research and Development, Merck Healthcare KGaA, Darmstadt, Germany.
- Department of Gynaecology and Reproductive Medicine, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany.
- Scientific-Clinical Centre for Endometriosis of the University Hospitals of Saarland, Saarbrücken, Germany.
- Fertility Centre Hamburg, Hamburg, Germany.
- Global Clinical Development, Research and Development, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, Massachusetts, USA.
Zitieren
APA
Strezsak, V., Allignol, A., Bühler, K., Fischer, R., Hubbard, J., Longobardi, S., Lispi, M., Schertz, J., & Verpillat, P. (2023). Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000530360
Vancouver
Strezsak V, Allignol A, Bühler K, Fischer R, Hubbard J, Longobardi S, et al. Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study. Gynecologic and Obstetric Investigation. 2023. doi:10.1159/000530360
BibTeX
@article{Strezsak2023,
author = {Strezsak, Valerie and Allignol, Arthur and Bühler, Klaus and Fischer, Robert and Hubbard, Julie and Longobardi, Salvatore and Lispi, Monica and Schertz, Joan and Verpillat, Patrice},
title = {Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study},
journal = {Gynecologic and Obstetric Investigation},
year = {2023},
doi = {10.1159/000530360}
}
EUVIMED